{
  "id": "a8caa16b7431ba7c",
  "title": "Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative",
  "description": "20260121T160000Z",
  "content": "",
  "source": "investing.com",
  "source_url": "https://www.investing.com/analysis/johnson--johnson-clears-the-patent-cliff-as-2026-guidance-resets-the-narrative-200673620",
  "published_at": "20260121T160000Z",
  "fetched_at": "2026-01-22T00:25:11.997161+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.investing.com/analysis/johnson--johnson-clears-the-patent-cliff-as-2026-guidance-resets-the-narrative-200673620",
    "url_mobile": "https://m.investing.com/analysis/johnson--johnson-clears-the-patent-cliff-as-2026-guidance-resets-the-narrative-200673620?ampMode=1",
    "title": "Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative",
    "seendate": "20260121T160000Z",
    "socialimage": "https://i-invdn-com.investing.com/redesign/images/seo/investingcom_analysis_og.jpg",
    "domain": "investing.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}